N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO RE49850
SERIAL NO

17591158

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AUCENTRA THERAPEUTICS PTY LTDADELAIDE SA 5000

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Wang, Shudong Adelaide, AU 58 382
Yu, Mingfeng Artarmon, AU 9 0
Zeleke, Solomon Tadesse Adelaide, AU 6 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 27, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 27, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 27, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00